Enzyme potentiated desensitization, or EPD, is a treatment for allergies developed in the 1960s by Dr. Len McEwen in the United Kingdom. EPD uses much lower doses of antigens than conventional treatment, with the addition of an enzyme, beta glucuronidase. EPD is available in the United Kingdom and Canada for the treatment of hay fever, food allergy and intolerance and environmental allergies.
EPD was under development for the treatment of autoimmune disease by a United Kingdom company called Epidyme also owned by Dr. McEwen which has been granted a United Kingdom patent. Despite encouraging results in an experimental model of rheumatoid arthritis the company was placed into liquidation in April 2010.
Read more about Enzyme Potentiated Desensitization: United States Use, EPD Treatment, Mechanism For EPD, Evidence For The Effectiveness of EPD, Safety of EPD, Comparison of EPD With Conventional Escalating-dose Immunotherapy (hyposensitization), Restrictions On EPD